A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients

European Heart Journal

Volumn 32, Issue 4, 2011, Pages 469-475

  Versmissen, Jorie ^a   Oosterveer, Daniëlla M ^a   Yazdanpanah, Mojgan ^a   Mulder, Monique ^a   Dehghan, Abbas ^a   Defesche, Joep C ^b   Kastelein, John J P ^b   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ABCA1; Coronary disease; Familial hypercholesterolemia; Pharmacogenetics; Statin

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT;

ADULT; ANALYSIS OF VARIANCE; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79951843559     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq208     Document Type: Article

References (41)

1. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14. (Pubitemid 36559596)
2. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-112.
3. Mohrschladt MF, Westendorp RG, Gevers Leuven JA, Smelt AH. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2004;172:329-335. (Pubitemid 38173008)
4. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
5. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 2005;280:22212-22221. (Pubitemid 40827878)
6. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109:II42-II48.
7. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002;90:731-736. (Pubitemid 35279392)
8. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93. (Pubitemid 28042271)
9. Maitland-van der Zee AH, Klungel OH, Stricker BH, Verschuren WM, Kastelein JJ, Leufkens HG, de Boer A. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213-222. (Pubitemid 34615811)
10. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006;51:822-826. (Pubitemid 44386828)
11. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005;16:19-25. (Pubitemid 40333362)
12. Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis. Vasc Med 2005;10:109-119. (Pubitemid 40883248)
13. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T. Sterol regulatory element-binding protein-2-and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanisms underlying the unique response to cellular cholesterol status. J Biol Chem 2007;282:21090-21099. (Pubitemid 47099939)
14. Baldan A, Bojanic DD, Edwards PA. The ABCs of sterol transport. J Lipid Res 2008;50:S80-S85.
15. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008;263:256-273. (Pubitemid 351207349)
16. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006;99:1031-1043. (Pubitemid 44729927)
17. Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet 2002;61:115-125. (Pubitemid 36372616)
18. Tan JH, Low PS, Tan YS, Tong MC, Saha N, Yang H, Heng CK. ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore. Hum Genet 2003;113:106-117. (Pubitemid 36869023)
19. Tregouet DA, Ricard S, Nicaud V, Arnould I, Soubigou S, Rosier M, Duverger N, Poirier O, Mace S, Kee F, Morrison C, Denefle P, Tiret L, Evans A, Deleuze JF, Cambien F. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler Thromb Vasc Biol 2004;24:775-781. (Pubitemid 38451619)
20. Ergen A, Isbir S, Tekeli A, Isbir T. Investigation of ABCA1 C69T and G-191C polymorphisms in coronary artery disease. In vivo 2008;22:187-190. (Pubitemid 351523555)
21. Porchay-Balderelli I, Pean F, Emery N, Maimaitiming S, Bellili N, Travert F, Mohammedi K, Roussel R, Marre M, Fumeron F. Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and high-density lipoprotein cholesterol and coronary heart disease in a population with type 2 diabetes mellitus. Metabolism 2009;58:74-79.
22. van Aalst-Cohen ES, Jansen AC, Boekholdt SM, Tanck MW, Fontecha MR, Cheng S, Li J, Defesche JC, Kuivenhoven JA, Kastelein JJ. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet 2005;13:1137-1142. (Pubitemid 41486224)
23. Hodoglugil U, Williamson DW, Huang Y, Mahley RW. Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. Atherosclerosis 2005;183:199-212. (Pubitemid 41579269)
24. Porchay I, Pean F, Bellili N, Royer B, Cogneau J, Chesnier MC, Caradec A, Tichet J, Balkau B, Marre M, Fumeron F. ABCA1 single nucleotide polymorphisms on highdensity lipoprotein-cholesterol and overweight: the D.E.S.I.R. study. Obesity (Silver Spring) 2006;14:1874-1879. (Pubitemid 46127363)
25. Slatter TL, Jones GT, Williams MJ, van Rij AM, McCormick SP. Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. Clin Genet 2008;73:179-184.
26. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53-58. (Pubitemid 32095642)
27. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007;59:483-499.
28. Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol 2008;51:388-395. (Pubitemid 351572238)
29. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2008;51:449-455.
30. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol 2007;17:227-236.
31. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Int Med 2004;256:482-490. (Pubitemid 39577582)
32. Jansen AC, van Aalst-Cohen ES, Hutten BA, Buller HR, Kastelein JJ, Prins MH. Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 2005;58:269-274. (Pubitemid 40249469)
33. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001;109:602-615. (Pubitemid 34051414)
34. Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta 2009;1791:563-572.
35. Huuskonen J, Abedin M, Vishnu M, Pullinger CR, Baranzini SE, Kane JP, Fielding PE, Fielding CJ. Dynamic regulation of alternative ATP-binding cassette transporter A1 transcripts. Biochem Biophys Res Commun 2003;306:463-468. (Pubitemid 36683096)
36. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang YZ, Zhang LH, James E, Wilson JE, Francone O, McManus BM, Hayden MR. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002;82:273-283. (Pubitemid 34242521)
37. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RF Jr, Neufeld ED, Remaley AT, Fredrickson DS, Brewer HB Jr, Santamarina-Fojo S. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and ApoE - knockout mice. Proc Natl Acad Sci USA 2002;99:407-412. (Pubitemid 34060374)
38. Joyce CW, Wagner EM, Basso F, Amar MJ, Freeman LA, Shamburek RD, Knapper CL, Syed J, Wu J, Vaisman BL, Fruchart-Najib J, Billings EM, Paigen B, Remaley AT, Santamarina-Fojo S, Brewer HB Jr. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem 2006;281:33053-33065.
39. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006;26:929-934. (Pubitemid 43732174)
40. Brunham LR, Singaraja RR, Duong M, Timmins JM, Fievet C, Bissada N, Kang MH, Samra A, Fruchart JC, McManus B, Staels B, Parks JS, Hayden MR. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:548-554.
41. Genvigir FD, Hirata MH, Hirata RD. ABCA1 expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics 2009;10:997-1005.